Toward an off-the-shelf vaccine for B-cell malignancies.
While idiotype vaccines have shown promise for B-cell malignancies, production is cumbersome; thus, targeting a common antigen on malignant B cells using an off-the-shelf approach would provide significant logistical advantages.
National Cancer Institute, USA.
James L
JL
Gulley
D000951:Antigens, Neoplasm / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D016393:Lymphoma, B-Cell / Q000276:immunology* / Q000628:therapy*; D011518:Proto-Oncogene Proteins / Q000276:immunology*
D000951:Antigens, Neoplasm; D011518:Proto-Oncogene Proteins; C090851:TCL1A protein, human